Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) on Tuesday, soared 3.49% from the previous trading day, before settling in for the closing price of $21.19. Within the past 52 weeks, CPRX’s price has moved between $13.00 and $24.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4106.79% annually for the last half of the decade. The company achieved an average annual earnings per share of 93.39%. With a float of $105.83 million, this company’s outstanding shares have now reached $107.12 million.
In an organization with 167 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 82.32%, operating margin of 37.78%, and the pretax margin is 41.0%.
Catalyst Pharmaceuticals Inc (CPRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Catalyst Pharmaceuticals Inc is 11.27%, while institutional ownership is 75.60%. The most recent insider transaction that took place on Nov 26 ’24, was worth 286,705. Before that another transaction happened on Nov 20 ’24, when Company’s Chief Med. & Reg. Officer sold 38,000 for $21.20, making the entire transaction worth $805,562. This insider now owns 51,391 shares in total.
Catalyst Pharmaceuticals Inc (CPRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.29 earnings per share (EPS) for the period falling under the consensus outlook (set at 0.46) by -0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.39% per share during the next fiscal year.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Catalyst Pharmaceuticals Inc (CPRX) is currently performing well based on its current performance indicators. A quick ratio of 4.92 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.68. Likewise, its price to free cash flow for the trailing twelve months is 13.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.17, a number that is poised to hit 0.34 in the next quarter and is forecasted to reach 1.59 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was inferior than the volume of 1.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.93%. Additionally, its Average True Range was 0.71.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 74.24%, which indicates a significant increase from 38.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.18% in the past 14 days, which was higher than the 37.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.17, while its 200-day Moving Average is $17.69. However, in the short run, Catalyst Pharmaceuticals Inc’s stock first resistance to watch stands at $22.26. Second resistance stands at $22.58. The third major resistance level sits at $23.15. If the price goes on to break the first support level at $21.37, it is likely to go to the next support level at $20.80. Assuming the price breaks the second support level, the third support level stands at $20.48.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
Market capitalization of the company is 2.62 billion based on 119,273K outstanding shares. Right now, sales total 398,200 K and income totals 71,410 K. The company made 128,700 K in profit during its latest quarter, and 43,880 K in sales during its previous quarter.
